Navigation Links
Memory Loss Linked to Cognitive Disorders

A new study has developed the first images of the physical changes in brain cells thought to underlie memory thus linking memory loss to cognitive disorders.

Earlier studies have established that a physiological effect known as long-term potentiation (LTP) encodes everyday forms of memory.

In neuroscience, LTP is an increase in the strength of a chemical synapse that lasts from minutes to several days. It is widely considered one of the major mechanisms by which memories are formed and stored in the brain.

The study was conducted by a team of researchers led by Christine M. Gall and Gary Lynch at the University of California, Irvine.

As part of the study, researchers collected brain tissues from rats and mice, which was kept alive in specially constructed equipment and induced LTP by stimulating synapses with a rhythm known to be critical to memory formation.

The brain slices were then sectioned and stained with one antibody that attaches to activated proteins involved with LTP and a second one that labels synapses. Newly developed microscopic methods were used to visualize and measure synapses that had both antibodies attached.

Researchers found with the images that the size and shape of synapses were changed by LTP.

It was shown how LTP deficiencies accompany the memory loss seen during the early stages of Huntingtons disease, an incurable neurodegenerative disease characterized by disturbances to memory and learning.

The way is now open to mapping where in the brain memories are laid down. Seeing memory-related physical changes to synapses means that we can at last use mouse models to test if the effects of retardation, aging and various cognitive disorders involve a specific, long-suspected defect in the connections between cortical neurons, Lynch said.

Scientists also found that LTP structures encoding memory were defective in mouse mod els of Huntingtons disease. They discovered that these synaptic defects could be fully reversed through treatment with a brain growth factor released at synapses.

Ampakines, a new class of drugs developed by researchers that is currently in clinical development for Alzheimers disease and ADHD, increase the levels of this growth factor and potentially emerge as a therapy for the cognitive problems associated with Huntingtons.

The findings of the study were published in the May issue of the Journal of Neuroscience.


Related medicine news :

1. Memory problem? solve a crossword
2. Deep Sleep Doesnt Increase Memory
3. For a Better Memory
4. Memory loss associated with microbes
5. Memory loss always goes hand with Depression
6. Memory deprivation after operations
7. Sage Improves Memory
8. Memory said to automatically improve with age
9. Enzyme Associated with Memory
10. Enzyme Associated With Memory
11. New Drug Combination Found To Improve Memory in Alzheimer’s Patient
Post Your Comments:

(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Australia,s successful biotechnology scientists, Dr Graham ... Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is seeking ... ASX. Noxopharm is a clinic-ready company with its first ... study later this year. NOX66 ... cancer patients - the ability of cancers to become resistant to ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology: